Loading the records…
Loading the records…
The Affordable Prescriptions for Patients Act (S1041), currently held at the desk in the House, limits patent assertions in biosimilar litigation, reducing barriers for biosimilar competition. This is bullish for pure-play biosimilar companies like Coherus ($CHRS) and supports Amgen's ($AMGN) biosimilar segment. The bill is part of a broader legislative push to lower drug costs, with related bills S891 and HR1768 reinforcing the theme.
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
The bill, if enacted, would structurally lower litigation costs for biosimilar entrants, benefiting $CHRS and $AMGN's biosimilar business. The broader legislative environment supports drug pricing reform, adding tailwinds to the biosimilar sector. Originator-heavy companies like $ABBV and $JNJ may face headwinds, but the impact is mitigated by their diversified portfolios.
The Affordable Prescriptions for Patients Act (S1041) was introduced in the Senate on March 13, 2025, by Senator Cornyn (R-TX) with bipartisan cosponsors including Senators Blumenthal, Grassley, and Durbin. It passed the Senate on April 10, 2025, and was received in the House on July 21, 2026, where it is currently held at the desk. The bill amends Title 35 of the U.S. Code to limit the number of patents that a biologic drug manufacturer (reference product sponsor) can assert in a patent infringement lawsuit against a biosimilar applicant. Specifically, the sponsor may assert no more than 20 patents total, with no more than 10 that issued after a certain date. This directly targets the practice of 'patent thickets' that delay biosimilar entry.
The bill does not authorize or appropriate any funding; it changes the rules of patent litigation. The mechanism is a statutory cap on patent assertions, which reduces the cost and uncertainty for biosimilar developers. The obligated parties are originator biologic companies (e.g., AbbVie, Johnson & Johnson, Roche) that must now prioritize which patents to assert. The direct consequence is that biosimilar applicants face lower legal barriers, enabling faster market entry and increased competition.
The convergence with related bills S891 (Bipartisan Health Care Act) and HR1768 (Lower Costs for Everyday Americans Act) indicates a broader congressional focus on reducing prescription drug costs. While these bills have different specific mechanisms, they share the objective of lowering healthcare expenses, creating a supportive legislative environment for biosimilar competition.
Structural winners are pure-play biosimilar companies like Coherus ($CHRS), which have no originator revenue to lose and stand to gain from accelerated biosimilar launches. Amgen ($AMGN) is a more complex case: its biosimilar business benefits, but its originator portfolio faces headwinds. However, given Amgen's strategic shift toward biosimilars, the net effect is positive. Losers include originator-heavy companies with large patent portfolios, such as AbbVie ($ABBV) and Johnson & Johnson ($JNJ), which may see earlier biosimilar competition.
The timeline: The bill is in the House, where it may be referred to committee or brought to a vote. Given bipartisan support and the current legislative calendar, passage in the 119th Congress is plausible but not guaranteed. Investors should monitor House action.
Matched on shared policy language across AI analyses, with ticker & timing weight
Expedited Access to Biosimilars Act
Biosimilars Access and Affordability Act
A bill to amend the Public Health Service Act to streamline the review of biosimilar biological products.
Biosimilars Access and Affordability Act
Executive orders & memoranda affecting the same sectors or companies
This executive order establishes a Women's Health Division within the NIH to coordinate and accelerate research on understudied women's health conditions, and creates a White House Women's Health Task Force to drive policy reforms and translation of research into clinical practice across federal agencies. It directs specific agencies to prioritize research, data collection, and translation into prevention, diagnosis, and treatment, with a focus on all life stages from infancy through aging.
This executive order directs the Secretaries of State, Labor, and Homeland Security to coordinate with Commerce, Education, and the SBA when processing H-1B petitions, and requires them to consider whether the employer has engaged in layoffs of similarly situated U.S. workers within the past year. It also orders the Labor Department to review past labor condition applications for potential enforcement actions against sponsoring employers, effectively tightening scrutiny on H-1B usage, especially by outsourcing firms.
This proclamation orders the Secretaries of War and Veterans Affairs to mandate rapid, ongoing digital sharing of military personnel and medical records, deploy AI-powered tools for benefits applications, and update existing IT contracts for interoperability. It also requires the Transition Assistance Program to connect separating service members to specific jobs or training programs before discharge.
Free — no credit card
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →